Portuguese Institute of Oncology of Coimbra Francisco Gentil

The Portuguese Institute of Oncology of Coimbra Francisco Gentil, EPE (IPO Coimbra) is today a reference institution in providing healthcare to oncology patients. With full accreditation since 2005 by Caspe Healthcare Knowledge Systems (CHKS) and since 2011 by the Organization of European Cancer Institutes (OECI) as a Clinical Cancer Center, IPO Coimbra has been strengthening its role in the healthcare network of the Central Region, the community of patients and families it serves, and among its partners, fostering a sense of proximity and humanization.

With multidisciplinarity as a fundamental premise in Oncology, it carries out its activities in Multidisciplinary Pathology Groups, focusing on patient care throughout the disease process and in all its dimensions. From this perspective, it is organized around the expectations and needs of patients and families, committing to implementing the best clinical practices in terms of access, quality and safety, productivity, and economic-financial performance, within a culture of responsibility, sustainability, and social cohesion.

Research is a strategic pillar of Clinical Governance and the Institution for the 2021-2023 triennium. Addressing the challenges of knowledge in Oncology requires adopting a strategic vision for research, development, and innovation, promoting the convergence of different fields of knowledge, streamlining access to support structures for research projects, maximizing human capital through the integration of multidisciplinary projects, in cooperation with other research units or centers, both national and international, thus enhancing the scientific evidence that underpins the provision of better healthcare to oncology patients.

With the recent restructuring of the Research Coordinating Office, IPO Coimbra is investing in skilled professionals capable of developing clinical, basic, and translational research, having established the Research Fund, which will enable the funding of research through the awarding of prizes and grants. Thus, it recognizes clinical trials as essential for achieving clinical excellence in Oncology.